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Naples, Naples, ItalyAbstractThe impact of the cannabinoid receptor 2 (CB2) rs35761398
polymorphism on chronic hepatitis B (CHB) was evaluated in
106 consecutive biopsy-proven CHB patients naive for antiviral
therapy. A histological activity index (HAI) > 8 (Ishak scoring)
was more frequent in patients with CB2-63 RR than in those
with CB2-63 QR or QQ (37% vs. 16.7%, p < 0.05). The logistic
regression analysis identiﬁed CB2-63 RR (p < 0.05) and a ﬁbrosis
score >3 (p < 0.005) as independently associated with an HAI
>8. The observation that the CB2-63 RR variant is an
independent predictor of extensive necroinﬂammation opens up
new prospects in the study of CHB.
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N. Coppola and R. Zampino contributed equally to this work.© 2015 Clinical Microbiology and Infection published by ElIntroductionComorbidities and several lifestyle, virus- and host-related
factors have been linked to the severity of chronic hepatitis B
(CHB) [1–5]. In patients with chronic hepatitis C virus infec-
tion, recent studies demonstrated an association between the
severity of the liver disease and the rs35761398 polymorphism
of the cannabinoid (CB) receptor 2 gene, which leads to the
substitution of glutamine Gln (Q) with arginine Arg (R) at
codon 63 [6,7]. In vitro studies indicated that this poly-
morphism may play a role in the pathogenesis of chronic
hepatitis C by affecting the ability of CB receptor 2 to exert its
inhibitory function, because T lymphocytes from CB2-63 RR
homozygotes showed an approximately two-fold reduction
in the endocannabinoid-induced inhibition of proliferation
compared to cells from CB2-63 QQ homozygotes [8,9].Materials and methodsThe present investigation evaluated whether the CB2 63 vari-
ants might affect the clinical presentation and predict the
outcome of CHB in 106 hepatitis B surface antigen/hepatitis B
virus (HBV) DNA-positive consecutive, asymptomatic Cauca-
sian patients naive for antiviral therapy. Patients were enrolled
from July 2009 to December 2013 at the time they underwent
a percutaneous liver biopsy under ultrasound guidance using a
modiﬁed Menghini needle. The need for liver biopsy was
established in each case by the physicians in care, and informed
consent was obtained. No patient had any complication after
liver biopsy. Liver specimens of at least 2 cm in length and with
more than 11 portal tracts were obtained and examined by a
skilled pathologist who, unaware of clinical data, graded nec-
roinﬂammation and ﬁbrosis by the Ishak scoring system [10]
and liver steatosis by a partially modiﬁed Kleiner scoring sys-
tem [11,12] (score 1 for fatty deposition in 1% to 10% of
hepatocytes, score 2 in 11% to 31%, score 3 in 31% to 60% and
score 4 in >60%). Patients with antibodies to HIV, hepatitis D
virus or hepatitis c virus and those with autoimmune hepatitis
were excluded. The demographics, risk factors for parenteral/
sexual transmission of infections and lifestyle habits were
recorded in a precoded questionnaire. The study was approved
by the Ethics Committee of the AOU-Second University of
Naples.
Plasma samples of all patients were tested for HBV DNA
and HBV genotype as previously described [13]. Molecular
screening for the CNR2 rs35761398 polymorphism (CAA/
CGG) underlying the CB2 Q63R substitution was performedClin Microbiol Infect 2015; 21: 609.e1–609.e4
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Germany) [6].
Continuous variables were summarized as mean and stan-
dard deviation and evaluated by an unpaired Student t test, and
categorical variables as absolute and relative frequencies and
evaluated by a χ2 test. Nonnormally distributed variables were
log-transformed. A general linear model was used for the
multivariate analysis. Statistical analysis was performed using
Statgraphics CENTURION XV.II (Adalta, Arezzo-Italy).ResultsThe majority of the patients enrolled were infected with HBV
genotype D (88.7%) and were hepatitis B e antigen–negative
(95.2%). The median age was 47 years (range 21 to 69), and male
subjects predominated (74.5%). Nine (8.49%) patients had a
history of previous intravenous drug use and 10 (9.4%) of active
alcohol abuse (more than 30g/d for female and 40g/d for male
subjects over the last 6 months). The prevalences of patients
showing CB2-63 QQ, QR and RR variants were 9.4%, 41.5% and
49.1%, respectively, according to the Hardy-Weinberg equilib-
rium (p 0.875). The demographic, biochemical, virological and
histological data analysed according to the CB2-63 variants are
shown in Table 1. The patients with the CB2-63 RR variant had a
higher histological activity index (HAI) than those with the CB2-
63 QR or QQ variant (mean 7.27 ± 3.16 vs. 5.84 ± 2.93 and
6.1 ± 1.49, respectively), differences not statistically signiﬁcant
probably because of the low number of QQ patients. In fact,
when this analysis considered RR vs. QR+QQ subjects, theTABLE 1. Demographic, biochemical, histological and virological ch
63 variants
CB2 RR
Number of patients 52
Mean age (±SD) 46.17 ± 10.7
Male, n (%) 39 (75)
Alcohol abusers (>30 g/d), n (%) 4 (7.69)
Intravenous drug users, n (%) 5 (9.61)
Body mass index (mean ± SD) 25.8 ± 3.9
AST, IU/L (mean ± SD) 74 ± 53
ALT, IU/L (mean ± SD) 111 ± 89
Total cholesterol (mean ± SD), mg/dL 178 ± 32.6
Triglycerides (mean ± SD), mg/dL 93.4 ± 31.7
Iron (mean ± SD), ug/dL 102.2 ± 46.5
Ferritin (mean ± SD), ng/mL 112.1 ± 89.6
γGT (mean ± SD), IU/mL 42.3 ± 48.2
Glucose (mean ± SD), mg/dL 91.75 ± 22.56
HBV DNA (mean ± SD) 2,829,170 ± 12,273,183
HBV genotype, n (%)
D 26 (90.4)
Non-D 5 (9.6)
HAI (mean ± SD) 7.269 ± 3.16
Fibrosis (mean ± SD) 2.85 ± 1.46
Steatosis (mean ± SD) 0.922 ± 0.94
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, γ-glutamyltransferase
*p Value still signiﬁcant after correcting for multiple testing.
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QR+QQ; p 0.0263). Moreover, moderate or severe necroin-
ﬂammation (HAI >8) was more frequent in the 52 patients with
CB2-63 RR than in the 54 with CB2-63 QR or QQ (37% vs.
16.7%, p < 0.05). The patients with the CB2-63 QQ variant
showed a higher steatosis score (1.9 ± 2.2) than those with the
CB2-63 RR or QR variant (0.9 ± 0.94 and 1.1 ± 0.99, respec-
tively; p < 0.05), but the percentage of cases with severe stea-
tosis (score>3) were similar in these variant subgroups, possibly
suggesting that worsening in steatosis may be independent of the
CB2-63 variants.
Patients with an HAI >8 showed a higher ﬁbrosis score
(mean 3.66 ± 1.24 vs. 2.44 ± 1.3, p < 0.0001) and a higher
prevalence of patients with the CB2-63 RR variant (67.9% vs.
42.3%, p < 0.05) (Table 2). A multivariate logistic regression
analysis including the CB2-63 variants (CB2-63 RR vs. others),
ﬁbrosis scores, age, sex, body mass index and HBV DNA
showed that the CB2-63 RR variant and a ﬁbrosis score >3
were the only independent predictors of necroinﬂammation >8
(p < 0.05 and p < 0.005, respectively) (Supplementary Table 1).DiscussionThe present study, the ﬁrst investigating the role of the canna-
binoid receptor type 2 in CHB, showed the CB2-63 RR variant
to be independently associated with the more severe degrees of
necroinﬂammation. In previous studies the CB2-63 RR variant
was associated with some autoimmune pathologies such as celiac
disease and childhood immune thrombocytopenic purpuraaracteristics in HBsAg–positive patients according to the CB2-
CB2 QR CB2 QQ p*
44 10 —
47.4 ± 11.5 45.2 ± 14.25 0.800
34 (77.27) 6 (60) 0.765
4 (9) 2 (20) 0.811
3 (6.8) 1 (10) 0.878
26.17 ± 3.6 25.9 ± 3.0 0.921
78 ± 6 69 ± 32 0.946
134 ± 99 102 ± 53 0.552
176 ± 32.9 187 ± 26.0 0.55
98.2 ± 33.3 85.1 ± 22.2 0.075
104.6 ± 34.9 106.5 ± 13.9 0.128
126.1 ± 115.0 136.2 ± 88.1 0.382
41.9 ± 23.16 48.7 ± 31.46 0.845
90.0 ± 18.85 91.9 ± 8.6 0.299
7,769,350 ± 1,035,956 109,808 ± 33,429,955 0.698
22 (93.2) 8 (90) 0.8766
3 (6.8) 1 (10)
5.84 ± 2.93 6.1 ± 1.49 0.117
2.86 ± 1.41 2.69 ± 0.96 0.442
1.051 ± 0.99 1.91 ± 2.18 0.0323
; HBV, hepatitis B virus; HAI, histological activity index.
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TABLE 2. Demographic, biochemical, histological and genetic characteristics in HBsAg–positive patients according to the HAI
HAI<0–8 HAI >8 p*
Number of patients 78 28
Mean age (±SD) 45.98 ± 11.85 48.28 ± 9.64 0.358
Male, n (%) 59 (75.6) 20 (71.4) 0.852
Alcohol abusers (>30 g/d), n (%) 8 (10.25) 2 (7.14) 0.91
Intravenous drug users, n (%) 9 (11.5) 0 0.13
Body mass index (mean ± SD) 26.08 ± 3.5 25.6 ± 4.26 0.559
AST, IU/L (mean ± SD) 71 ± 52 82 ± 48 0.383
ALT, IU/L (mean ± SD) 3.2 ± 3.42 2.79 ± 1.77 0.547
γGT (mean ± SD), IU/mL 45.88 ± 42.47 41.3 ± 18.76 0.583
Total cholesterol (mean ± SD), mg/dL 176.98 ± 31.8 181.42 ± 33.33 0.597
Triglycerides (mean ± SD), mg/dL 98.2 ± 32.7 90.28 ± 27.95 0.279
Iron (mean ± SD), ug/dL 108.8 ± 38.01 112.44 ± 44.45 0.703
Ferritin (mean ± SD), ng/mL 146.6 ± 109.9 148.32 ± 77.74 0.939
Glucose (mean ± SD), mg/dL 92.35 ± 19.27 90.39 ± 22.4 0.659
HBV DNA, IU/mL (mean ± SD) 5,485,060 ± 2,128,680 6,587,478 ± 1,961,599 0.782
HBV genotype, n (%)
D 72 (92.3) 25 (89.3) 0.789
Non-D 6 (7.7) 3 (10.7)
CB2-63 QQ, n (%) 9 (11.5) 1 (3.6) 0.38
CB2-63 QR, n (%) 36 (46) 8 (28.57) 0.16
CB2-63 RR, n (%) 33 (42.3) 19 (67.85) 0.035
Fibrosis (mean ± SD) 2.44 ± 1.3 3.66 ± 1.24 0.000
Patients with ﬁbrosis score 5 or 6, n (%) 6 (7.69) 8 (28.6) 0.13
Steatosis (mean ± SD) 1.15 ± 1.26 0.89 ± 0.916 0.320
Patients with steatosis score 3 or 4, n (%) 9 (11.5) 2 (7.1) 0.416
HAI, histological activity index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, γ-glutamyltransferase; HBV, hepatitis B virus.
*p Value still signiﬁcant after correcting for multiple testing.
CMI Coppola et al. Impact of the CB2-63 polymorphism in CHB 609.e3[14–16]. Accordingly, the mechanism of liver cell necrosis in
acute and chronic hepatitis B resembles that of autoimmune
hepatitis, because HBV is not directly cytopathic and liver cell
necrosis is due to a cell-mediated immune reaction in which the
presensitized cytotoxic T-cells bind to the HBV core antigen and
to a human leukocyte class II antigen on the surface of HBV-
infected hepatocytes and introduce necrotizing cytokines to
these cells [17]. In addition, endocannabinoids and their re-
ceptors play an important role in other chronic liver diseases,
because they have been found to be involved in the pathogenesis
of liver ﬁbrosis in alcohol-related hepatitis, in obesity-related
liver steatosis [18–20] and in chronic hepatitis C [6,7]. In line
with these studies, our data identiﬁed an independent association
between the CB2-63 RR variant and more extensive liver cell
necroinﬂammation in CHB. We concede that the sample size of
this study does not allow deﬁnitive conclusions to be drawn and
that the data presented need conﬁrmation. It does, however,
open up new promising prospects in the study of CHB.Transparency declarationThis study was supported by a grant from PRIN 2008, M.I.U.R.,
Rome, Italy “OTTIMIZZAZIONE DELLA DIAGNOSI EZIO-
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